Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of subcutaneous risankizumab induction in moderately to severely active Crohn's disease
CTR20242118Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Aug 2024; status: active.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20242118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242118.